Pharmacokinetic study of the new cyclosporin-a formulation (Neoral™ in adult allogeneic bone marrow transplant recipients

Haematologica

Volumn 86, Issue 3, 2001, Pages 311-315

  Dotti, G ^a   Gaspari, F ^a   Caruso, R ^a   Perico, N ^a   Remuzzi, G ^a   Barbui, T ^a   Rambaldi, A ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Allogeneic bone marrow transplantation; Cyclosporin A; Graft versus host disease; Immunosuppression

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; THIOTEPA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; FEMALE; GRAFT VERSUS HOST REACTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MALE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; TREATMENT OUTCOME;

ADULT; AGED; AREA UNDER CURVE; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035067759     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Cyclosporine as prophylaxis for graft-varsus-host disease: A randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic laukemia
2. Pharmacodynamic studies of cyclosporine in marrow transplant recipients. A comparison of three assay methods
3. Serum cyclosporine concentration and risk of acute graft-versus-host disease after allogeneic marrow transplantation
4. Graft-versus-host disease
5. Pharmacokinetic monitoring of cyclosporine in allogeneic bone marrow transplants
6. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients
7. Cyclosporine
8. Clinical variability of cyclosporine pharmacokinetics in adult and pediatric petients after renal, cardiac, hepatic, and bone-marrow transplants
9. A new microemulsion formulation of cyclosporin: Pharmacokinetic and clinical features
10. Pharmacokinetics and tolerability of a microemulsion formulation of cyclosporine in renal allograft recipients: A concentration-controlled comparison with the commercial formulation
11. A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation
12. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmune to Neoral
13. Comparison of Neoral and Sandimmune for induction and maintenance immunosuppression after kidney transplantation
14. Cyclosporine monitoring in renal transplantation: Area under the curve monitoring is superior to trough-level monitoring
15. Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: Report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997)
16. Prediction of cyclosporine area under the curve using a three-point sampling strategy after Neoral administration
17. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: A randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate
18. Thrombotic microangiopathy following bona marrow transplantation
19. Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive graft-versus-host disease prophylaxis
20. Pharmacokinetic profile of cyclosporine in long-term heart transplanted patients treated with new oral formulation
21. Canadian Consensus Meeting on cyclosporine monitoring: Report on the consensus panel
22. Pharmacology of cyclosporine (sandimmune) III. Immunochemistry and monitoring
23. Cyclosporine. A review of its pharmacodynamic and pharmacokinetic properties, and therepeutic use in immunoregulatory disorders
24. Therapeutic monitoring of cyclosporine: Impact of a change in standards on 125I-monoclonal RIA performance in comparison with liquid chromatography
25. New oral formulation of cyclosporin A (Neoral) pharmacokinetics in allogeneic bone marrow transplant recipients